Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772]

Ann Oncol. 2022 Mar;33(3):355. doi: 10.1016/j.annonc.2021.12.008. Epub 2022 Jan 7.
No abstract available

Publication types

  • Published Erratum